Trial Information

Summary: Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer (VENICE)

The primary objective of the study is to demonstrate an improvement of overall survival in patients treated with aflibercept versus placebo, in patients receiving docetaxel/ prednisone

Patient Inclusion Criteria:

  • Histologically- or cytologically-confirmed prostate adenocarcinoma
  • Metastatic disease
  • Progressive disease while receiving hormonal therapy or after surgical castration
  • Effective castration

Patient Exclusion Criteria:

  • Prior cytotoxic chemotherapy for prostate cancer, except estramustine and except adjuvant/neoadjuvant treatment completed > 3 years ago
  • Prior treatment with VEGF inhibitors or VEGF receptor inhibitors
  • Eastern Cooperative Oncology Group performance status > 2

Primary Outcomes: Overall survival

Key Secondary Outcomes: PSA measurement, pain measurement, occurrence of skeletal related events

Contact:

Cathy Spears, Director Research
St. Francis Hospital and Health Centers
1500 N Albany St., suite 1001
Beech Grove, IN 46107
Telephone: 317-782-7819
Fax: 317-782-7828
Email:

Profile Page: St. Francis Hospital and Health Centers, Beech Grove, IN

If you would like to learn more about participating in this study, please send an e-mail message using the form below.

*Subject:

Name:

Address:

City:

State:

*Zip:

*Country:

Phone:

*Email address:

Message:

Please note: A number of commercial online services display an error message after you click on Send. Please be assured that your message has been received.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 22, 2008 at 2:59:15 PM


Back to Centerwatch Trial Listing by Location


Additional resources
in this illness area

Copyright © 1995 - 2008, CenterWatch
All Rights Reserved

This site was developed in association with Illumina Interactive, Boston, MA